{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hoppe MM"],"funding":["Cancer Research UK","National Research Foundation Singapore","National Medical Research Council"],"pagination":["e13366"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8103098"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(5)"],"pubmed_abstract":["Early relapse after platinum chemotherapy in epithelial ovarian cancer (EOC) portends poor survival. A-priori identification of platinum resistance is therefore crucial to improve on standard first-line carboplatin-paclitaxel treatment. The DNA repair pathway homologous recombination (HR) repairs platinum-induced damage, and the HR recombinase RAD51 is overexpressed in cancer. We therefore designed a REMARK-compliant study of pre-treatment RAD51 expression in EOC, using fluorescent quantitative immunohistochemistry (qIHC) to overcome challenges in quantitation of protein expression in situ. In a discovery cohort (n = 284), RAD51-High tumours had shorter progression-free and overall survival compared to RAD51-Low cases in univariate and multivariate analyses. The association of RAD51 with r"],"journal":["EMBO molecular medicine"],"pubmed_title":["Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer."],"pmcid":["PMC8103098"],"funding_grant_id":["NMRC/TA/0052/2016","NMRC/CIRG/1400/2014","NMRC/CSA‐INV/0016/2017"],"pubmed_authors":["Jaynes P","Sedukhina AS","Lim S","Choi H","Upadhyayula SS","Pitt JJ","Jeyasekharan AD","Lim DGZ","Wardyn JD","Karnezis A","Huntsman DG","Pang BNK","Tan TZ","P S Yeong J","Scott CL","Chiu DS","Tan DSP","Topp MD","Patel NR","Lie S","Sato K","Hoppe MM","Kaye SB","Leung S","Brown R"],"additional_accession":[]},"is_claimable":false,"name":"Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.","description":"Early relapse after platinum chemotherapy in epithelial ovarian cancer (EOC) portends poor survival. A-priori identification of platinum resistance is therefore crucial to improve on standard first-line carboplatin-paclitaxel treatment. The DNA repair pathway homologous recombination (HR) repairs platinum-induced damage, and the HR recombinase RAD51 is overexpressed in cancer. We therefore designed a REMARK-compliant study of pre-treatment RAD51 expression in EOC, using fluorescent quantitative immunohistochemistry (qIHC) to overcome challenges in quantitation of protein expression in situ. In a discovery cohort (n = 284), RAD51-High tumours had shorter progression-free and overall survival compared to RAD51-Low cases in univariate and multivariate analyses. The association of RAD51 with r","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2026-05-09T08:20:05.364Z","creation":"2022-02-10T09:57:05.099Z"},"accession":"S-EPMC8103098","cross_references":{"pubmed":["33709473"],"doi":["10.15252/emmm.202013366"]}}